Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia

Treatment paradigms for acute myeloid leukemia (AML) have evolved at a rapid pace in recent years. The combination of venetoclax with a hypomethylating agent prolonged survival in clinical trials when compared to hypomethylating agent monotherapy. However, little is known about the performance of ve...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouligny, Ian M., Murray, Graeme, Doyel, Michael, Patel, Tilak, Boron, Josh, Tran, Valerie, Gor, Juhi, Hang, Yiwei, Alnimer, Yanal, Zacholski, Kyle, Venn, Chad, Wages, Nolan A., Grant, Steven, Maher, Keri R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Haematologic Malignancy ‐ Myeloid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188504/
https://www.ncbi.nlm.nih.gov/pubmed/37206255
http://dx.doi.org/10.1002/jha2.663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188504/
https://www.ncbi.nlm.nih.gov/pubmed/37206255
http://dx.doi.org/10.1002/jha2.663

Ejemplares similares